Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers

The resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib or erlotinib, is considered a major challenge in the treatment of patients with non-small cell lung cancer (NSCLC). Herein, we identified the critical roles of anterior gradient 2 (AGR2) in gefitinib (Gef) resistance of mutant NSCLC cells.Using datasets from a pair of NSCLC-sensitive and NSCLC-resistant cells, immunoblotting,...